title: Characterization of 4-(2-hydroxyphenyl)-1-[2'-[N-(2''-pyridinyl)-p-fluorobenzamido]ethyl]piperazine (p-DMPPF) as a new potent 5-HT1A antagonist.
abstract: OBJECTIVE
  The identification of potent and selective radioligands for the mapping of 5-HT receptors is interesting both for clinical and experimental research. The aim of this study was to compare the potency of a new putative 5-HT(1A) receptor antagonist, p-DMPPF, (4-(2-hydroxyphenyl)-1-[2'-[N-(2''-pyridinyl)-p-fluorobenzamido]ethyl]piperazine) with that of the well-known 5-HT(1A) antagonists, WAY-100635 (N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethyl]-N-(2-pyridinyl) cyclohexanecarboxamide) and its fluorobenzoyl analogue, p-MPPF (4-(2-methoxyphenyl)-1-[2'-[N-(2''-pyridinyl)-p-fluorobenzamido]ethyl]piperazine).
  
  
  METHODS
  Single cell extracellular recordings of dorsal raphe (DR) neurones were performed in rat brain slices. The potency of each compound at antagonizing the effect of the 5-HT(1A) agonist, 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)-tetraline], was quantified using the Schild equation. The pharmacological profile of p-DMPPF was defined using competition binding assays.
  
  
  RESULTS
  Consistently with a 5-HT(1A) receptor antagonist profile, incubation of slices with an equimolar (10 nM) concentration of each compound markedly reduced the inhibitory effect of 8-OH-DPAT on the firing rate of DR neurones, causing a significant rightward shift in its concentration-response curve. The rank order of potency of the antagonists was WAY-100635>p-DMPPF>or=p-MPPF. The sensitivity of DR neurones to the inhibitory effect of 8-OH-DPAT was found to be heterogeneous. The binding experiments demonstrated that p-DMPPF is highly selective for 5-HT(1A) receptors, with a K(i) value of 7 nM on these receptors.
  
  
  CONCLUSIONS
  The potency of the new compound, p-DMPPF, as a 5-HT(1A) antagonist is similar to that of p-MPPF in our electrophysiological assay. Its selectivity towards 5-HT(1A) receptors makes it a good candidate for clinical development.
authors: Cyclotron Research Center, Liege University, Liege, Belgium.
authors: C
authors: C
authors: Defraiteur
authors: A
authors: A
authors: Plenevaux
authors: J
authors: J
authors: Scuvée-Moreau
authors: N
authors: N
authors: Rouchet
authors: D
authors: D
authors: Goblet
authors: A
authors: A
authors: Luxen
authors: V
authors: V
authors: Seutin
mesh_terms: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000494:pharmacology; D000631:Aminopyridines / Q000494:pharmacology; D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D001667:Binding, Competitive / Q000187:drug effects; D004594:Electrophysiology; D066298:In Vitro Techniques; D007700:Kinetics; D008297:Male; D009474:Neurons / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology*; D011485:Protein Binding; D011725:Pyridines / Q000494:pharmacology; D011869:Radioligand Assay; D011903:Raphe Nuclei / Q000166:cytology / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D044282:Receptor, Serotonin, 5-HT1A / Q000187:drug effects*; D012702:Serotonin Antagonists / Q000494:pharmacology*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology
chemical_list: C513932:4-(2'-hydroxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-fluorobenzamido)ethyl)piperazine; D000631:Aminopyridines; D001549:Benzamides; D010879:Piperazines; D011725:Pyridines; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D044282:Receptor, Serotonin, 5-HT1A; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; C099463:4-(2' methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-fluorobenzamido)ethyl)piperazine
references: Nucl Med Biol. 2000 Jul;27(5):467-71
references: 10962252
references: Nucl Med Biol. 2006 Jul;33(5):667-75
references: 16843842
references: J Nucl Med. 2002 Mar;43(3):292-303
references: 11884487
references: Neuroscience. 2003;116(3):669-83
references: 12573710
references: Neuroscience. 2003;122(1):193-204
references: 14596860
references: J Neurophysiol. 2004 Feb;91(2):994-1005
references: 14573555
references: J Comp Neurol. 2004 Jun 28;474(3):364-78
references: 15174080
references: J Neurosci. 1981 Oct;1(10):1148-54
references: 6793698
references: Brain Res. 1983 Dec 19;289(1-2):109-19
references: 6140982
references: J Neurosci. 1988 Sep;8(9):3499-506
references: 3171686
references: Synapse. 1987;1(1):3-9
references: 3505364
references: Annu Rev Pharmacol Toxicol. 1990;30:307-48
references: 2188571
references: Ann N Y Acad Sci. 1990;600:114-29; discussion 129-31
references: 2252305
references: Ann N Y Acad Sci. 1990;600:93-103; discussion 103
references: 2123618
references: Naunyn Schmiedebergs Arch Pharmacol. 1990 Nov;342(5):502-7
references: 1982557
references: Eur J Pharmacol. 1991 Aug 29;201(2-3):163-9
references: 1839146
references: Psychopharmacol Ser. 1993;10:15-25
references: 8361973
references: J Med Chem. 1993 Oct 15;36(21):3161-5
references: 8230102
references: Trends Pharmacol Sci. 1993 Dec;14(12):41-8
references: 8122313
references: J Med Chem. 1994 May 13;37(10):1406-7
references: 8182697
references: Br J Pharmacol. 1994 Jul;112(3):873-80
references: 7921615
references: Pharmacol Rev. 1994 Jun;46(2):157-203
references: 7938165
references: Eur J Pharmacol. 1995 Jul 25;281(1):81-8
references: 8566121
references: Behav Brain Res. 1996;73(1-2):337-53
references: 8788530
references: Nucl Med Biol. 1996 May;23(4):487-90
references: 8832704
references: Synapse. 1996 Aug;23(4):344-6
references: 8855520
references: Eur J Nucl Med. 1998 Apr;25(4):338-46
references: 9553162
references: Nucl Med Biol. 1998 May;25(4):343-50
references: 9639295
references: J Pharmacol Exp Ther. 1999 Sep;290(3):1258-69
references: 10454502
references: J Neurophysiol. 2004 Dec;92(6):3532-7
references: 15254076
references: J Neurosci. 2006 Jan 4;26(1):193-202
references: 16399687
references: Nucl Med Biol. 2000 Jul;27(5):493-7
references: 10962257